Topical oxymetazoline hydrochloride 1.0% effectively reduces persistent facial erythema of rosacea on day 1

Introduction: Persistent facial erythema is a bothersome, therapeutically challenging feature of rosacea; therapies with clear efficacy at treatment onset are needed. In 2 identically designed, phase 3 pivotal, randomized, multicenter, double-blind, parallel-group, vehicle-controlled, 29-day REVEAL trials, topical oxymetazoline cream 1.0% significantly reduced moderate to severe persistent facial erythema of rosacea. A post hoc analysis of pooled data from both trials assessed erythema reduction on day 1.